Higher rate of heart problems with Amgen osteoporosis drug in trial

(Reuters) - Amgen Inc and UCB SA on Sunday said they do not expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late stage clinical trial.